There are 2949 resources available
450P - The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC): Updated analysis
Presenter: Takeshi Kawakami
Session: E-Poster Display
Resources:
Abstract
451P - Novel somatic genetic variants as predictors of resistance to EGFR-targeted therapies in metastatic colorectal cancer patients
Presenter: Pau Riera
Session: E-Poster Display
Resources:
Abstract
452P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Presenter: Vaia Florou
Session: E-Poster Display
Resources:
Abstract
453P - QUAlity of LIfe and survival of meTAStatic colorectal cancer patients treated with trifluridine-tipiracil (QUALITAS)
Presenter: Patricia Hamers
Session: E-Poster Display
Resources:
Abstract
455P - A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing
Presenter: Aparna Parikh
Session: E-Poster Display
Resources:
Abstract
454P - Comparative study of metronomic capecitabine and oxaliplatin versus classic XELOX in Egyptian patients with metastatic colorectal cancer
Presenter: Raghda Abu El Ela
Session: E-Poster Display
Resources:
Abstract
456P - Tumor response to irinotecan is associated with IL-10 expression level in metastatic colorectal cancer - Results from mCRC biomarker study
Presenter: Jinjia Chang
Session: E-Poster Display
Resources:
Abstract
457P - 1st-line panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany: Interim results of the non-interventional study VALIDATE
Presenter: Jens Uhlig
Session: E-Poster Display
Resources:
Abstract
458P - Phase (Ph) I/Ib trial of fruquintinib (fru) in patients (pts) with advanced solid tumors: Preliminary results of the dose expansion (exp) cohort in refractory metastatic colorectal cancer (mCRC)
Presenter: N. Arvind Dasari
Session: E-Poster Display
Resources:
Abstract
459P - Effect of RAS amplification (RASa) on outcomes to EGFR monoclonal antibody therapy (EGFRmAb) in metastatic colorectal cancer (mCRC)
Presenter: Marwan Fakih
Session: E-Poster Display
Resources:
Abstract